Advisor Resource Council Takes Position in Danaher Co. (NYSE:DHR)

Advisor Resource Council bought a new position in shares of Danaher Co. (NYSE:DHR) in the third quarter, Holdings Channel.com reports. The firm bought 1,014 shares of the conglomerate’s stock, valued at approximately $282,000.

Other large investors have also recently modified their holdings of the company. Financial Enhancement Group LLC increased its stake in Danaher by 6.1% in the third quarter. Financial Enhancement Group LLC now owns 11,081 shares of the conglomerate’s stock valued at $3,081,000 after acquiring an additional 641 shares during the last quarter. Graypoint LLC raised its holdings in shares of Danaher by 1.4% during the 3rd quarter. Graypoint LLC now owns 14,131 shares of the conglomerate’s stock valued at $3,929,000 after buying an additional 199 shares in the last quarter. Concurrent Investment Advisors LLC lifted its position in Danaher by 2.9% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 3,787 shares of the conglomerate’s stock worth $1,053,000 after buying an additional 108 shares during the last quarter. Ballast Advisors LLC boosted its stake in Danaher by 1.4% in the third quarter. Ballast Advisors LLC now owns 3,751 shares of the conglomerate’s stock worth $1,043,000 after buying an additional 50 shares in the last quarter. Finally, Harvest Portfolios Group Inc. grew its position in Danaher by 1.2% during the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after acquiring an additional 2,465 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR opened at $246.10 on Friday. Danaher Co. has a 12-month low of $192.35 and a 12-month high of $281.70. The company has a market cap of $177.75 billion, a price-to-earnings ratio of 46.97, a price-to-earnings-growth ratio of 4.54 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a fifty day simple moving average of $265.79 and a two-hundred day simple moving average of $260.75.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the company posted $2.02 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. Research analysts predict that Danaher Co. will post 7.51 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is presently 20.61%.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on DHR shares. The Goldman Sachs Group boosted their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. TD Cowen raised their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. UBS Group decreased their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, Royal Bank of Canada lowered their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.